Creates an international reference price cap for prescription drugs and biological products sold in the United States, requires manufacturers to report pricing and supply data annually, directs the Secretary of Health and Human Services to calculate capped prices each year, and authorizes civil monetary penalties for manufacturers who sell above the cap. The Secretary must issue implementing guidance and regulations to carry out the reporting, price calculation, and enforcement processes.